Ginkgo

AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production

Retrieved on: 
Wednesday, March 27, 2024
Research, Eating, AQUA, Tenderness, Mercury, Pesticide, Health, Taste, Polychlorinated biphenyl, Tuna, Whale, Regeneration, Today, Partnership, Risk, Ginkgo, DNA, Business development, Dolphin, Doctor of Philosophy, Diet, Fermentation, Cholesterol, Shellfish, Animal, Allergen, Food industry, Aquaculture

CHICAGO and BOSTON, March 27, 2024 /PRNewswire/ -- AQUA Cultured Foods, a food tech company producing alternative seafood options through the use of microbial fermentation, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. AQUA has chosen Ginkgo to help optimize its innovative fermentation technology to elevate the quality of its fish-free seafood products that authentically replicate the look, feel, and taste of fresh-caught seafood. Leveraging Ginkgo's microbial characterization and analytics, along with AQUA's proprietary strains and processes, the partners aim to transform the future of alt-seafood production.

Key Points: 
  • AQUA has chosen Ginkgo to help optimize its innovative fermentation technology to elevate the quality of its fish-free seafood products that authentically replicate the look, feel, and taste of fresh-caught seafood.
  • Leveraging Ginkgo's microbial characterization and analytics, along with AQUA's proprietary strains and processes, the partners aim to transform the future of alt-seafood production.
  • With Ginkgo, AQUA hopes to amplify its R&D capabilities and further optimize its consortium to establish consistent, high-quality products.
  • Stefan Baier, PhD, Chief Science Officer of AQUA Cultured Foods: "Today marks a significant step towards revolutionizing alternative seafood production.

ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network

Retrieved on: 
Wednesday, March 13, 2024
AAV, Partnership, Ginkgo, SVP, DNA, AI, Ecosystem, Corporate development, Vaccine

This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications.

Key Points: 
  • This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications.
  • This also marks ProteoNic's joining the Ginkgo Technology Network, a groundbreaking ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
  • ProteoNic's premium vector technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology.
  • "Their expertise and premium technology adds tremendous value to our network, enhancing our ability to provide comprehensive solutions to our customers across various biotech sectors."

ProteoNic Announces Partnership with Ginkgo Bioworks and Joins the Ginkgo Technology Network

Retrieved on: 
Wednesday, March 13, 2024
AAV, Partnership, Ginkgo, SVP, DNA, AI, Ecosystem, Corporate development, Vaccine

This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications.

Key Points: 
  • This strategic alliance will grant Ginkgo Bioworks' customers access to ProteoNic's state of the art vector technology in the field of protein production as well as to novel viral vector technology for cell and gene therapy applications.
  • This also marks ProteoNic's joining the Ginkgo Technology Network, a groundbreaking ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
  • ProteoNic's premium vector technology is broadly applicable across cell lines and product classes, including complex molecules which are difficult to express by conventional technology.
  • "Their expertise and premium technology adds tremendous value to our network, enhancing our ability to provide comprehensive solutions to our customers across various biotech sectors."

bit.bio Announced as Inaugural Partner of Ginkgo Bioworks’ New Technology Network

Retrieved on: 
Wednesday, February 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Technology, Genetics, Therapy, Investment, Synthetic biology, Culture, Drug development, Drug discovery, Ginkgo, Network, Ecosystem, Biology, DNA, Mobile phone

bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.

Key Points: 
  • bit.bio, the company coding human cells for novel cures, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced bit.bio as an inaugural partner of the Ginkgo Technology Network.
  • The Network, launched today, is a groundbreaking ecosystem of cutting edge technology partners, committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.
  • As a Network partner, bit.bio’s ioCells portfolio of human cells for research and drug discovery can be integrated into Ginkgo’s platform ecosystem.
  • bit.bio’s ioCells products are precision reprogrammed from iPSCs using bit.bio’s opti-ox TM technology.

Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Acquisition, DNA, RSV, Engineering, Enzyme, CRISPR, SARS-CoV-2, Gene editing, Library, Biology, MIT, Harvard University, Cell, Broad Institute, RNA, Patient, Intellectual property, DRS, AAV, Ginkgo, Partnership

Proof was founded by gene editing pioneer Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs.

Key Points: 
  • Proof was founded by gene editing pioneer Dr. Feng Zhang of the Broad Institute of MIT and Harvard, Drs.
  • Gene editing systems have revolutionized the therapeutics industry, enabling a vast array of potential programmable medicines.
  • Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Ginkgo is committed to building world-class capabilities in engineering genetic medicines.
  • Integrating Proof's technologies and libraries gives our customers a new tool to overcome the limitations of current gene editing systems.

Ginkgo Bioworks Acquires Reverie Labs Platform, Enhancing AI-Driven Drug Discovery Capabilities for Customer Programs

Retrieved on: 
Wednesday, February 28, 2024
Cloud, Acquisition, Google Cloud, DNA, Pfizer, Merck, Architecture, Chemistry, AI, SVP, Reverie, Drug discovery, Owl, Health, Foundry, RNA, Boehringer Ingelheim, Corporate development, Machine learning, Biology, Head, Ginkgo, Software, Partnership

BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.

Key Points: 
  • BOSTON, Feb. 28, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of Reverie Labs, which built and used AI/ML tools to accelerate drug discovery.
  • Ginkgo has acquired Reverie's infrastructure and software for training large-scale AI foundation models and four of Reverie's key AI team members will join Ginkgo.
  • The acquisition is intended to strengthen Ginkgo's AI/ML-driven discovery services offering and to accelerate Ginkgo's work to build next-generation biological foundation models .
  • Reverie's generative AI platform for chemistry will also be added into Ginkgo's capabilities to support small molecule programs.

Ginkgo Bioworks Announces Participation in the 44th Annual TD Cowen Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
DNA, Ginkgo, Entrepreneurship, Conference, Online shopping

BOSTON, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m.

Key Points: 
  • BOSTON, Feb. 27, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is scheduled to participate in Cowen's 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 2:10 p.m.
  • ET.
  • The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
  • To ask a question ahead of the presentation, please submit them to @ Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2023 Results Presentation

Retrieved on: 
Thursday, February 22, 2024
DNA, Q&A, Ginkgo, Online shopping

BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m. ET.

Key Points: 
  • Presentation and Q&A session scheduled for post-market on Thursday, February 29, 2024
    BOSTON, Feb. 22, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, beginning at 5:30 p.m.
  • ET.
  • The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.
  • To ask a question ahead of the presentation, please submit them to @ Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected] .

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

Retrieved on: 
Thursday, February 15, 2024
DNA, Saponin, GMD, Toxicity, Enzyme, Ginkgo Bioworks, Medicine, SVP, Partnership, Animal, Vaccine, ADC, Refrigeration, Vaccination, Shingles, Malaria, COVID-19, Respiratory syncytial virus, Chemical substance, Saccharomyces cerevisiae, CBD, DTRA, Protein, MCDC, QS-21, Plague, Ginkgo

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.

Key Points: 
  • Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination.
  • Currently, only a handful of adjuvants are available for human use in licensed vaccines.
  • Ginkgo will develop a first-generation Adjuvant Development Candidate (ADC) production method, using a heterologous production strain such as brewers' yeast, Saccharomyces cerevisiae.
  • Development of a first-generation ADC production method could facilitate further development of a sustainable mass-production manufacturing process for these complex adjuvants.

Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval

Retrieved on: 
Thursday, February 1, 2024
Partnership, Nature, Food security, USDA, Plant, Science, Research, DNA, Genetics, Petunia, Gene, USD, Flower, Synthetic biology, Ginkgo Bioworks, Firefly, Ginkgo, Garden, Luminescence, Phosphorus

The new research builds on an earlier discovery for creating continuously glowing plants by inserting DNA obtained from the mushrooms.

Key Points: 
  • The new research builds on an earlier discovery for creating continuously glowing plants by inserting DNA obtained from the mushrooms.
  • Light Bio is excited to begin taking orders today for its category-defining Firefly Petunias, available at www.light.bio , today.
  • Light Bio chose the petunia as its first product because it is one of the most popular ornamental plants in the world.
  • In addition to the pure joy these plants bring, the underlying science also helps to elucidate the molecular physiology of plants.